Effect of conventional and sustained release sodium valproate on serum leptin and some liver function tests in epileptic patients

Sajid Kh Ameen*, Faris A Ahmed**

*Department of Pharmacology, College of Medicine, **Department of Physiology, Ninevah College of Medicine, University of Mosul, Correspondence: faris_mawjood@yahoo.com

ABSTRACT

Objectives: To compare the effect between conventional and sustained released sodium valproate monotherapy on serum leptin, body mass index (BMI) and some liver function tests including serum alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), albumin, total bilirubin (TB) and direct bilirubin (DB) in epileptic patients.

Patients and methods: The study is a case control study. It included 40 epileptic patients on conventional sodium valproate at doses 400-800 mg per day, and 42 patients on sustained released sodium valproate at doses 500-1000 mg per day. Forty healthy subjects sex and age matched served as controls were also included in the study. Blood samples were taken from the patients and controls and analyzed for serum ALT, ALP, AST, albumin, total bilirubin and direct bilirubin. Serum leptin was also analyzed by using ELISA technique.

Results: Serum leptin, ALT, ALP, AST and TB in epileptic patients treated by conventional sodium valproate were significantly (p < 0.05) higher than that in patients treated with sustained release sodium valproate. However, serum albumin was significantly (p < 0.05) lower than that in patients treated by sustained released sodium valproate. No significant change was noticed between the two patients groups for BMI and serum DB

Conclusion: Sustained release sodium valproate may have less hepatotoxic effect and cause less weight gain than conventional sodium valproate. The reduced frequency of doses and the possibility of dosing flexibility may all improve compliance of the patients.

Keywords: Sodium Valproate, Liver function, epileptics.
Sodium valproate is the most effective antiepileptic drug in the treatment of idiopathic generalized epilepsy. It also possesses efficacy in the treatment of various epileptic seizures such as absence, myoclonic, and generalized tonic-clonic seizures.

Sustained (extended)-release formulations of valproic acid can be very helpful in achieving treatment objectives especially when switching from conventional to extended-release formulations of these agents. Stable serum levels without marked peak-to-trough fluctuations, reduced frequency of dosing, and the possibility of dosing flexibility may all improve compliance, seizure control or tolerability, particularly for tremor, patient satisfaction and ultimately quality of life.

Serum leptin and insulin levels were significantly elevated by sodium valproate in treated patients compared with untreated patients and with those received carbamazepin and lamotrigen therapy, suggesting that hyperleptinemia and hyperinsulinemia are common with sodium valproate among epileptic patients who gained weight as a sign of leptin and insulin resistance. However, sodium valproate did not cause a significant change in serum leptin in epileptic children.

Several studies of the side effect of conventional sodium valproate on liver function were conducted. However, few studies were done on the effect of sustained release sodium valproate on liver function. Kondo et al. suggested that sustained release formulation of sodium valproate may be safer on liver than conventional form of sodium valproate.

Since the effect of sustained release on BMI and serum leptin was not studied yet. In addition, the effect of sustained released sodium valproate on liver functions still need more evaluation. Therefore, this work was conducted in order to evaluate the effect of sustained released sodium valproate on BMI, serum leptin and some liver function tests. These results were compared with patients treated with conventional sodium valproate and with a control group.

**Patients and methods**

This work was conducted in a Private Clinic of Neurology in Mosul, during the period from October 2012 to June 2013. The study was approved by ethical committee of Ninevah Directorate (Health Medical Research Ethical Committee). Diagnosis and treatment of the patients were under supervision of a neurologist. The biochemical analysis was conducted at the Department of Pharmacology, College of Medicine, University of Mosul, Mosul, Iraq.

Two patient groups were included in this study. The first group included 40 patients, with age range 17-39 years (mean ± SD: 23.57 ± 5.59 years), with generalized tonic clonic epilepsy, on conventional sodium valproate (Depakine®, Sanofi-Aventis, France), at doses between 400 and 800 mg once or twice daily for at least six months. The second group included 42
patients with age range 17-38 years (mean ± SD: 23.89 ± 5.05), with
generalized tonic colonic epilepsy, on
sustained released sodium valproate
(Depakine chrono®, Sanofi-Aventis,
France), at doses between 500 and
1000 mg once or twice daily for at
least six months. Forty apparently
healthy volunteers as a control group
were judged free from disease or
medicine, with age range 17-38 years
(mean ± SD: 23.71 ± 5.41 years), were
also included in the study.

Five ml of venous blood samples
were taken from patients and controls,
at about 8.00 to 10.00 a.m., and after
an overnight fasting. The serum was
divided into 2 parts and kept at -20 °C,
the first aliquot was used for the
measurement of serum leptin14 and the
other aliquot was used for the
measurement of alkaline phosphatase
(ALP), alanine amino transpherase
(ALT), aspartate amino transpherase
(AST), albumin, total bilirubin (TB)
and direct bilirubin and albumin15.

Body mass index (BMI) was
measured using the following formula
BMI = weight (kg)/height (m)².16

Data are presented as mean ± SD and
were analyzed using Anova test and
Duncan’s test to compare among
different groups. Unpaired t-test was
used to compare between groups.

Correlation coefficient (r) was also
used to determine the relationship
between the parameters and age, dose
and duration of therapy. Statistical
Package for Social Sciences (SPSS)
version 17 was used for analysis of the
data17.

Results
Conventional sodium valproate
significantly increased (p < 0.05) BMI,
serum leptin, ALT, AST, ALP and TB
compared with the controls. However,
serum albumin and DB were not changed
significantly compared with the controls
(Table 1).

Sustained release sodium valproate
also significantly increased (p < 0.05)
serum leptin, AST and TB. On the other
hand, BMI, serum albumin, ALT, ALP
and serum DB did not change significantly
compared with the controls (Table 1).

Serum leptin, ALT, ALP, AST and TB
in patients treated by conventional sodium
valproate were significantly (p < 0.05)
higher than that in patients treated with
sustained release sodium valproate.
However, serum albumin was significantly
(p < 0.05) lower than that in patients
treated by sustained released sodium
valproate. No significant change was
noticed between the two groups for BMI
and serum DB as shown in Table 1.
Table 1. Effect of conventional and sustained released sodium valproate on different parameters

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control group</th>
<th>Conventional Sodium valproate group</th>
<th>Sustained released sodium valproate group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 40</td>
<td>N = 40</td>
<td>N = 42</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.35±1.82</td>
<td>23.76±2.78&lt;sup&gt;a&lt;/sup&gt;</td>
<td>22.74±2.22</td>
</tr>
<tr>
<td>Leptin (ng/L)</td>
<td>7.31±3.00</td>
<td>12.18±5.87&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.8±25.22&lt;sup&gt;bc&lt;/sup&gt;</td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td>4.17±0.41</td>
<td>4.02±0.56</td>
<td>4.29±0.42&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>21.61±7.20</td>
<td>38.87±7.18&lt;sup&gt;a&lt;/sup&gt;</td>
<td>25.30±6.68&lt;sup&gt;bc&lt;/sup&gt;</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>19.30±6.12</td>
<td>60.69±10.09&lt;sup&gt;a&lt;/sup&gt;</td>
<td>16.84±7.79&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>ALP (U/L)</td>
<td>67.71±17.64</td>
<td>130.02±40.38&lt;sup&gt;a&lt;/sup&gt;</td>
<td>66.10±17.50&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>TB (mg/dL)</td>
<td>0.65±0.25</td>
<td>1.25±0.27&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.85±0.21&lt;sup&gt;bc&lt;/sup&gt;</td>
</tr>
<tr>
<td>DB (mg/dL)</td>
<td>0.28±0.13</td>
<td>0.30±0.07</td>
<td>0.26±0.06</td>
</tr>
</tbody>
</table>

<sup>a,b</sup> p < 0.05 from the control group; <sup>c</sup> p < 0.05 from the conventional group. BMI, body mass index; AST, alanine aminotransferase; ALT, aspartate aminotransferase; ALP, alkaline phosphatase; TB, total bilirubin; DB, direct bilirubin

Discussion

The current study demonstrated significant increase in BMI in epileptic patients receiving conventional sodium valproate, but it was not confirmed with epileptic patients receiving sustained release sodium valproate. Other studies are in agreement with this study for the significant increase BMI by conventional sodium valproate in epileptic patients<sup>18,19</sup>. However, divalproex, the sustained released sodium valproate was associated with superior tolerability with less weight gain compared with conventional sodium valproate<sup>20</sup>. The results of this study revealed that serum leptin was significantly higher compared with the control group in epileptic patients receiving conventional sodium valproate and to a lesser extent with sustained released sodium valproate. These results were consistent for conventional sodium valproate with other workers<sup>9,21,22</sup>.

The two common homeostatic hormones, insulin and leptin, have been expected to form a common link to weight gain in epileptic patients receiving conventional sodium valproate<sup>23</sup>. In addition, appetite can be stimulated by increased GABA transmission within the hypothalamic axis of central nervous system by conventional sodium valproate<sup>24</sup>. Sodium valproate also caused direct secretion of leptin from adipocytes<sup>25</sup>. Serum ALT and AST and ALP were increased significantly in the present epileptic patients treated with conventional but not sustained released sodium valproate. The result regarding conventional sodium valproate group was in agreement with other studies<sup>26-29</sup>. The observed increase in enzyme activity in epileptic patients treated with conventional sodium valproate may be as a result of liver injury which
altered hepatocyte integrity caused by sodium valproate pharmacokinetic interactions. In addition, serum biochemical changes, which indicate predisposition to development of rickets or osteomalacia appear within 90 days of starting carbamazepine or valproic acid monotherapy.\(^{30,31}\)

The results showed significant increase in TB with no significant change in DB for both conventional and sustained release sodium valproate. The significant increase in TB with no significant changes in DB may be due to a defect in conjugation of bilirubin with glucuronate caused by the damaged hepatocytes leading to the leakage of bilirubin into circulation.\(^{32}\)

The altered pharmacokinetics and metabolism of sodium valproate after replacement of conventional sodium valproate with the slow-release formulation in epileptic patients, suggested smaller diurnal fluctuations in valproate concentrations during treatment with slow-release formulation of valproate resulted in lowered concentrations of the most toxic metabolites which associated with hepatotoxicity.\(^{13}\)

In conclusion, serum leptin and some liver function tests in patients treated with conventional sodium valproate were higher than in patients treated with sustained release sodium valproate. Sustained release sodium valproate can be more safe on liver functions with less adverse effect on BMI than conventional sodium valproate.

Acknowledgement
This work was supported by Mosul College of Medicine, University of Mosul.

Reference
19. Othman AO, Thanon IA. Effect of sodium valproate on serum leptin, C-reactive protein, oxidative stress and lipid profile in male epileptic patients. M.Sc. Thesis in pharmacology, College of Medicine, University of Mosul 2010.